PAM50-based ROR indexes as a tool to individualize the use of neoadjuvant endocrine therapy in ER+/HER2-breast cancer

被引：0
|
作者：
Lopez Velazco, J. I. [1 ]
Manzano, S. [1 ]
Elorriaga, K. [2 ]
Lahuerta Martinez, A. [3 ]
Alvarez, L. A. [4 ]
Etxabe Azkue, I. [4 ]
Huarte Martinez, M. [4 ]
Buch, E. [5 ]
Gimenez Climent, J. [6 ]
Quiroga Garcia, V. [7 ]
Aragon, S. [8 ]
Pare, L. [9 ]
Prat, A. [10 ]
Alvarez Lopez, I. [11 ,12 ]
Munoz Caffarel, M. [13 ,14 ]
Urruticoechea, A. [11 ,12 ]
机构：
[1] Biodonostia Hlth Res Inst, Dept Oncol, San Sebastian, Spain
[2] OSIDonostialdea Onkol, Pathol Unit, Gipuzkoa Pathol Unit, San Sebastian, Spain
[3] OSI Donostialdea Onkol, Dept Oncol, Gipuzkoa Canc Unit, San Sebastian, Spain
[4] General Surg Gynecol & Gen Surg Dept, Breast Unit, Onkol, San Sebastian, Spain
[5] Hosp Sagunto Hosp Clin Univ, Dept Oncol, Valencia, Spain
[6] Valencia Oncol Inst IVO, Dept Oncol, Valencia, Spain
[7] ICO Inst Catala Oncol Badalona Hosp Univ Germ, Dept Oncol, Badalona, Spain
[8] Hosp 12 Octubre, Dept Oncol, Madrid, Spain
[9] Hosp Clin Barcelona, Oncol Dept, Barcelona, Spain
[10] Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain
[11] Biodonostia Hlth Res Inst, Dept Oncol, San Sebastian, Spain
[12] OSI Donostialdea Onkol, Gipuzkoa Canc Unit, San Sebastian, Spain
[13] Biodonostia Hlth Res Inst, Oncol Dept, Bilbao, Spain
[14] Ikerbasque, Basque Fdn Sci, Bilbao, Spain
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.03.112
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
96P
引用
收藏
页码：S168 / S169
页数：2
相关论文
共 50 条
  • [41] Phase II study of adjuvant endocrine therapy with CDK 4/6 inhibitor, ribociclib, for localized ER+/HER2-breast cancer (LEADER, part 1)
    Spring, Laura M.
    Scarpetti, Lauren
    Niemierko, Andrzej
    Isakoff, Steven J.
    Moy, Beverly
    Wander, Seth A.
    Smith, Elisabeth
    Abraham, Elizabeth
    Shin, Jennifer
    Patel, Jaymin M.
    Comander, Amy
    Mulvey, Therese
    Bardia, Aditya
    [J]. CANCER RESEARCH, 2022, 82 (04)
  • [42] Real-world aromatase inhibitor use and failure in women with metastatic ER+/HER2-breast cancer.
    Landsman-Blumberg, Pamela
    Namjoshi, Madhav
    Thomson, Erin
    Johnson, William
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [43] PTCH1 and CTNNB1 emerge as pivotal predictors of resistance to neoadjuvant chemotherapy in ER+/HER2-breast cancer
    Ozcan, Gulnihal
    [J]. FRONTIERS IN ONCOLOGY, 2023, 13
  • [44] ASO Visual Abstract: Axillary Response to Neoadjuvant Therapy in Node-Positive ER+/HER2-Breast Cancer Patients-Predictors and Oncologic Outcomes
    Friedman-Eldar, Orli
    Ozmen, Tolga
    El Haddi, Salah James
    Goel, Neha
    Tjendra, Youley
    Kesmodel, Susan B.
    Moller, Mecker G.
    Franceschi, Dido
    Layton, Christina
    Avisar, Eli
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (07) : 4102 - 4102
  • [45] Community platinum use in neoadjuvant or adjuvant HER2-breast cancer.
    Bobolts, Laura Rose
    Armitage, Melissa
    Tamayo, Mary Michelle
    Hrushesky, William J.
    Kogler, Jurgen
    Schorer, Anna E.
    Wurtz, Kenneth
    Bennett, Charles L.
    Shimp, William S.
    Baranwal, Anmol
    Huff, Dinah Faith Q.
    Anthony, Carol
    Walton, Robert
    Fishman, Marc L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [46] ASO Author Reflections: The Changing Role of Gene Expression Profiling in ER+/HER2-Breast Cancer
    van Steenhoven, Julia E. C.
    van Dalen, T.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (Suppl 3) : S800 - S801
  • [47] Clinicopathological Factors Associated with Oncotype DX Risk Group in Patients with ER+/HER2-Breast Cancer
    Song, Ran
    Lee, Dong-Eun
    Lee, Eun-Gyeong
    Lee, Seeyoun
    Kang, Han-Sung
    Han, Jai Hong
    Lee, Keun Seok
    Sim, Sung Hoon
    Chae, Heejung
    Kwon, Youngmee
    Woo, Jaeyeon
    Jung, So-Youn
    [J]. CANCERS, 2023, 15 (18)
  • [48] Molecular stratification of ER+/HER2-breast cancer cell lines to predict sensitivity to targeted agents
    Bathurst, L.
    Liao, L.
    Crozier, C.
    Lyttle, N.
    Marcellus, R.
    Bayani, J.
    Al-Awar, R.
    Bartlett, J.
    Spears, M.
    [J]. CANCER RESEARCH, 2019, 79 (04)
  • [49] Role of androgen receptor expression in early stage ER+/PgR-/HER2-breast cancer
    Tagliaferri, Barbara
    Quaquarini, Erica
    Palumbo, Raffaella
    Balletti, Emanuela
    Presti, Daniele
    Malovini, Alberto
    Agozzino, Manuela
    Teragni, Cristina Maria
    Terzoni, Andrea
    Bernardo, Antonio
    Villani, Laura
    Sottotetti, Federico
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [50] Digistain: A Novel, Rapid, and Cost-effective Prognostic Marker for Guiding Adjuvant Therapy in ER+, HER2-Breast Cancer
    Amrania, Hemmel
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (SUPPL 2) : S321 - S321
12345